{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ondansetron+4+MG&page=2",
    "query": {
      "intervention": "Ondansetron 4 MG",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 82,
    "total_pages": 9,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ondansetron+4+MG&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ondansetron+4+MG&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-05T01:40:25.348Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01740401",
      "title": "CTLA-4 Blockade and Low Dose Cyclophosphamide in Patients With Advanced Malignant Melanoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Icahn School of Medicine at Mount Sinai",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2012-10",
      "completion_date": "2014-12",
      "has_results": true,
      "last_update_posted_date": "2017-12-06",
      "last_synced_at": "2026-10-05T01:40:25.348Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01740401"
    },
    {
      "nct_id": "NCT00641797",
      "title": "Treating Benign Paroxysmal Positional Vertigo (BPPV) in ED Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Benign Paroxysmal Positional Vertigo"
      ],
      "interventions": [
        {
          "name": "Meclizine",
          "type": "DRUG"
        },
        {
          "name": "Epley Maneuver",
          "type": "OTHER"
        },
        {
          "name": "Lorazepam",
          "type": "DRUG"
        },
        {
          "name": "Diphenhydramine",
          "type": "DRUG"
        },
        {
          "name": "Ondansetron",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Lehigh Valley Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2006-11",
      "completion_date": "2013-11",
      "has_results": true,
      "last_update_posted_date": "2018-04-03",
      "last_synced_at": "2026-10-05T01:40:25.348Z",
      "location_count": 1,
      "location_summary": "Allentown, Pennsylvania",
      "locations": [
        {
          "city": "Allentown",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00641797"
    },
    {
      "nct_id": "NCT07639723",
      "title": "Aprepitant to Improve Same Day Discharge for TKA",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "PONV"
      ],
      "interventions": [
        {
          "name": "Aprepitant Injection",
          "type": "DRUG"
        },
        {
          "name": "Ondansetron (Zofran)",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Endeavor Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 350,
      "start_date": "2026-07",
      "completion_date": "2027-08",
      "has_results": false,
      "last_update_posted_date": "2026-06-10",
      "last_synced_at": "2026-10-05T01:40:25.348Z",
      "location_count": 1,
      "location_summary": "Skokie, Illinois",
      "locations": [
        {
          "city": "Skokie",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07639723"
    },
    {
      "nct_id": "NCT02648490",
      "title": "An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumour"
      ],
      "interventions": [
        {
          "name": "HLX07",
          "type": "DRUG"
        },
        {
          "name": "Acetaminophen",
          "type": "DRUG"
        },
        {
          "name": "dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "diphenhydramine",
          "type": "DRUG"
        },
        {
          "name": "5-HT3 inhibitor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Henlix, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 19,
      "start_date": "2016-09",
      "completion_date": "2019-06-28",
      "has_results": false,
      "last_update_posted_date": "2019-07-30",
      "last_synced_at": "2026-10-05T01:40:25.348Z",
      "location_count": 1,
      "location_summary": "Fremont, California",
      "locations": [
        {
          "city": "Fremont",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02648490"
    },
    {
      "nct_id": "NCT00778011",
      "title": "Uncomplicated Nausea and Vomiting in the Emergency Department",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Nausea",
        "Vomiting"
      ],
      "interventions": [
        {
          "name": "Ondansetron",
          "type": "DRUG"
        },
        {
          "name": "Metoclopramide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "WellSpan Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 137,
      "start_date": "2005-11",
      "completion_date": "2006-12",
      "has_results": false,
      "last_update_posted_date": "2012-06-28",
      "last_synced_at": "2026-10-05T01:40:25.348Z",
      "location_count": 1,
      "location_summary": "York, Pennsylvania",
      "locations": [
        {
          "city": "York",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00778011"
    },
    {
      "nct_id": "NCT02542384",
      "title": "A Study Evaluating the Overall Pain Relief and Safety of Intravenous (IV) CR845 in Patients Undergoing Abdominal Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Post Abdominal Surgery Pain"
      ],
      "interventions": [
        {
          "name": "CR845 IV 1 mcg/kg",
          "type": "DRUG"
        },
        {
          "name": "CR845 IV 0.5 mcg/kg",
          "type": "DRUG"
        },
        {
          "name": "Placebo IV",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cara Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 451,
      "start_date": "2015-09",
      "completion_date": "2018-06",
      "has_results": false,
      "last_update_posted_date": "2019-05-31",
      "last_synced_at": "2026-10-05T01:40:25.348Z",
      "location_count": 23,
      "location_summary": "Sheffield, Alabama • New Haven, Connecticut • Bradenton, Florida + 20 more",
      "locations": [
        {
          "city": "Sheffield",
          "state": "Alabama"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Bradenton",
          "state": "Florida"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Maitland",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02542384"
    },
    {
      "nct_id": "NCT01566838",
      "title": "Continuous Subpleural Infusion of Bupivacaine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Postoperative Pain"
      ],
      "interventions": [
        {
          "name": "Subpleural pain catheter with infusion of 0.125% bupivacaine",
          "type": "DRUG"
        },
        {
          "name": "Standard acute pain management",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Inova Health Care Services",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 83,
      "start_date": "2012-10",
      "completion_date": "2015-12",
      "has_results": true,
      "last_update_posted_date": "2017-12-20",
      "last_synced_at": "2026-10-05T01:40:25.348Z",
      "location_count": 1,
      "location_summary": "Falls Church, Virginia",
      "locations": [
        {
          "city": "Falls Church",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01566838"
    },
    {
      "nct_id": "NCT00642512",
      "title": "Dronabinol Versus Standard Ondansetron Antiemetic Therapy in Preventing Delayed-Onset Chemotherapy-Induced Nausea and Vomiting",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chemotherapy Induced Nausea and Vomiting"
      ],
      "interventions": [
        {
          "name": "dronabinol",
          "type": "DRUG"
        },
        {
          "name": "ondansetron",
          "type": "DRUG"
        },
        {
          "name": "dronabinol/ondansetron",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Solvay Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 64,
      "start_date": "2003-07",
      "completion_date": "2004-07",
      "has_results": false,
      "last_update_posted_date": "2008-04-03",
      "last_synced_at": "2026-10-05T01:40:25.348Z",
      "location_count": 43,
      "location_summary": "Tucson, Arizona • Anaheim, California • Fountain Valley, California + 37 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Greenbrae",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00642512"
    },
    {
      "nct_id": "NCT03435003",
      "title": "Designing Optimal Prevention and Management of Postoperative Nausea and Emesis for Patients Undergoing Laparoscopic Sleeve Gastrectomy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Post-operative Nausea and Vomiting",
        "Laparoscopic Sleeve Gastrectomy"
      ],
      "interventions": [
        {
          "name": "Aprepitant 80 mg Oral Capsule",
          "type": "DRUG"
        },
        {
          "name": "scopolamine transdermal",
          "type": "DRUG"
        },
        {
          "name": "Total intravenous anesthesia",
          "type": "PROCEDURE"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Ondansetron",
          "type": "DRUG"
        },
        {
          "name": "Reglan",
          "type": "DRUG"
        },
        {
          "name": "Compazine",
          "type": "DRUG"
        },
        {
          "name": "Sugammadex",
          "type": "DRUG"
        },
        {
          "name": "Propofol",
          "type": "DRUG"
        },
        {
          "name": "dexmedetomidine",
          "type": "DRUG"
        },
        {
          "name": "Fentanyl",
          "type": "DRUG"
        },
        {
          "name": "Sevoflurane",
          "type": "DRUG"
        },
        {
          "name": "Desflurane",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Stony Brook University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 83,
      "start_date": "2017-08-28",
      "completion_date": "2019-04-01",
      "has_results": true,
      "last_update_posted_date": "2024-02-14",
      "last_synced_at": "2026-10-05T01:40:25.348Z",
      "location_count": 1,
      "location_summary": "Stony Brook, New York",
      "locations": [
        {
          "city": "Stony Brook",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03435003"
    },
    {
      "nct_id": "NCT04743661",
      "title": "131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Medulloblastoma",
        "Recurrent Ependymoma"
      ],
      "interventions": [
        {
          "name": "Irinotecan",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Omburtamab I-131",
          "type": "DRUG"
        },
        {
          "name": "Liothyronine",
          "type": "DRUG"
        },
        {
          "name": "SSKI",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Antipyretic",
          "type": "DRUG"
        },
        {
          "name": "Antihistamine",
          "type": "DRUG"
        },
        {
          "name": "anti-emetics",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pediatric Brain Tumor Consortium",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 62,
      "start_date": "2022-04-04",
      "completion_date": "2027-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-07-28",
      "last_synced_at": "2026-10-05T01:40:25.348Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • New York, New York • Cincinnati, Ohio",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04743661"
    }
  ]
}